News Breaks |
|
|
| March 21, 2013 |
| 10:53 EDT |  | FRAN, WHX, MCP, AMRN, EBIX | Options with decreasing implied volatility: WHX EBIX MCP FRAN AMRN
|
|
|
News For WHX;EBIX;MCP;FRAN;AMRN From The Last 14 Days Check below for free stories on WHX;EBIX;MCP;FRAN;AMRN the last two weeks. |
|
|
| May 17, 2013 |
| 14:12 EDT |  | AMRN | Amarin shares slip after FDA updates Orange Book
 Subscribe for More Information |
|
| May 15, 2013 |
| 11:28 EDT | | EBIX | Options with increasing implied volatility: BMY AGNC EBIX IAU
Subscribe for More Information |
|
| 11:04 EDT |  | AMRN | Amarin management to meet with Lazard Capital
Meeting to be held in the Mid-Atlantic area on May 16 hosted by Lazard Capital. |
|
| May 14, 2013 |
| 12:59 EDT |  | EBIX | Ebix downgraded to Neutral from Strong Buy at Tigress Financial
Subscribe for More Information |
|
| May 13, 2013 |
| 12:52 EDT | | AMRN | Amarin strength attributed to MassHealth drug list addition
Subscribe for More Information |
|
| May 10, 2013 |
| 14:14 EDT |  | MCP | Molycorp could see a short squeeze, says CIBC
Subscribe for More Information |
|
| 12:31 EDT |  | MCP | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 12:00 EDT |  | MCP | Molycorp rises 19.7%
Subscribe for More Information |
|
| 10:37 EDT |  | EBIX | Ebix reports Q1 EPS 45c, consensus 44c
Subscribe for More Information |
|
| 10:00 EDT | | MCP | Molycorp rises 17.5%
Subscribe for More Information |
| |
| 09:38 EDT | | MCP | Active equity option families trading
Subscribe for More Information |
|
| 09:23 EDT | | AMRN | Amarin continues to make progress with payors, says Leerink
Leerink reiterates an Outperform rating on shares of Amarin following the company's Q1 results. The firm believes Amarin continues to make good progress with payors and that Vascepa script trends are tracking well. |
|
| 09:21 EDT | | MCP | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 09:00 EDT | | MCP | Molycorp rises 9.3%
Subscribe for More Information |
|
| May 9, 2013 |
| 16:24 EDT | | MCP | Molycorp reports Q1 adjusted EPS (15c), consensus (27c)
Reports Q1 revenue $146.4M, consensus $137.52M. |
|
| 16:18 EDT | | AMRN | Amarin reports Q1 EPS (41c), consensus (39c)
Reports Q1 revenue $2.34M, consensus $5.2M. Amarin said its direct sales force, consisting of approximately 275 sales professionals, made sales calls to clinicians for two months in Q1. Amarin reports that, since launch, access to clinicians has been good, and that it has yet to hear any significant negative reaction to the efficacy or safety profile of Vascepa. Amarin said it continues to make significant progress in its effort to expand patent protection for Vascepa and now has 22 patents issued or allowed in the United States with over 30 additional U.S. patent applications being prosecuted. |
|
| 13:54 EDT | | MCP | Molycorp May 6 weekly straddle priced for 9.5% move into Q1
Subscribe for More Information |
|
| 13:15 EDT | | AMRN | Amarin, Omthera drop following fatty acids study in journal
Subscribe for More Information |
|
| 10:22 EDT | | MCP | Molycorp May volatility elevated into Q1 and expense outlook
Molycorp May weekly call option implied volatility is at 239, May is at 92, June is at 75, September is at 67; compared to its 26-week average of 75 according to Track Data, suggesting large near term price movement into the expected release of Q1 results today after the market close. |
|
| May 8, 2013 |
| 12:39 EDT | | EBIX | Options with increasing implied volatility: ALXA FIO EBIX VMED HNZ
Subscribe for More Information |
| |
|
|
|
|
